Last updated on September 2020

A Study to Evaluate Efficacy Safety Tolerability and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia

Brief description of study

The purpose of this study is to determine whether add-on TAK-831 is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).

Detailed Study Description

The drug being tested in this study is called TAK-831. TAK-831 is being tested to treat negative symptoms in participants who have schizophrenia.

The study will enroll approximately 234 participants. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups in the double-blind periodwhich will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • TAK-831 50 mg once daily
  • TAK-831 125 mg once daily
  • TAK-831 500 mg once daily
  • Placebo once daily

This multi-center trial will be conducted in the United States, Spain, Italy, Czech Republic, Poland, Bulgaria and Ukraine. The overall time to participate in this study is approximately 20 weeks. Participants will make 11 visits to the clinic, and will be followed up for safety assessment 10 to 14 days after the last dose of study drug (Day 98).

Clinical Study Identifier: NCT03382639

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.